News
QuidelOrtho to Report Second Quarter 2023 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech completes acquisition of Polyplus
Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Acadia Healthcare Opens the First of Two Hospitals Developed in Partnership With Geisinger
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest operating joint venture hospital, Geisinger Behavioral Health Center Northeast, located in Moosic
Transgene Receives $15.3 Million from the Sale of Securities Held for Sale
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Sangamo Therapeutics, Inc. (“Sangamo”, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Therapeutics (“Prevail”), a wholly
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Inogen Expands Its Respiratory Product Portfolio with Acquisition of Physio-Assist
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the company has entered into a definitive
Simulations Plus Releases ADMET Predictor® 11
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of ADMET Predictor®
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has received positive recognition from leading business and industry organisations as a leading
EQS-News: Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
Delaware District Court Permits NanoString’s Counterclaims that 10x Genomics and Harvard Violated the Antitrust Laws
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, provided comments on yesterday’s order of the United States District
Agilent Achieves Great Place to Work® Certification
Agilent Technologies Inc. (NYSE: A) today announced the company has achieved certification as a Great Place to Work®. The recognition reflects Agilent's commitment to creating a positive work
Agilent Announces Gen6 Software for BioTek Line of Microplate Readers
Agilent Technologies Inc. (NYSE: A) today announced the launch of new Gen6 software for all Agilent BioTek detection instruments. Featuring a broad range of prebuilt experiment templates for common
NanoString Provides Preliminary Financial and Operational Highlights for Second Quarter of 2023
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its
Acadia Healthcare Announces Date for Second Quarter 2023 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2023 results on Thursday, July 27, 2023, after the close of the market. Acadia will conduct a
Dexcom Schedules Second Quarter 2023 Earnings Release and Conference Call for July 27, 2023 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023. Management will hold a conference call
Dexcom Schedules Second Quarter 2023 Earnings Release and Conference Call for July 27, 2023 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023. Management will hold a conference call
OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist:
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that the trial’s Independent Drug Safety Monitoring Board (DSMB) provided a positive
Poxel, winner of the 2023 edition of the I-nov contest
Regulatory News:
POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the United States Patent and Trademark Office has granted a new patent protecting Tedopi®, a